NCT05219253 - A Study on the Immune Response and Safety of a Vaccine Against Herpes Zoster in Adults Aged 50 Years and Older in India | Biotech Hunter

Enrollment

288

Participants

Timeline

Start Date

February 2, 2022

Primary Completion Date

October 11, 2022

Study Completion Date

December 12, 2022

Conditions

Herpes Zoster

Interventions

BIOLOGICAL

HZ/su

Two doses of the HZ/su vaccine administered intramuscularly, one each at Day 1 and Month 2.

DRUG

Placebo

Two doses of Placebo (lyophilised sucrose reconstituted with saline \[NaCl\] solution) administered intramuscularly, one each at Day 1 and Month 2.

Trial Locations (9)

GSK Investigational Site, New Delhi

GSK Investigational Site, Chandigarh

GSK Investigational Site, Kanpur

GSK Investigational Site, Ahmedabad

GSK Investigational Site, Pune

GSK Investigational Site, Mysore

GSK Investigational Site, North Guwāhāti

GSK Investigational Site, Visakhapatnam

GSK Investigational Site, Mumbai